Published Medical Literature

Targeted Therapies Drive Declining Multiple Myeloma Mortality in the United States

Elranatamab Demonstrates Cost-Effectiveness Advantage Over Teclistamab in Advanced Myeloma

Central Nervous System Involvement in Multiple Myeloma: Emerging Diagnostic and Therapeutic Strategies

Global Burden of Multiple Myeloma in Adolescents and Young Adults Projected to Increase

Elevated Infection Risk in Smoldering Multiple Myeloma: New Evidence from iStopMM

Modakafusp Alfa Shows Efficacy in Relapsed/Refractory Multiple Myeloma

Prognostic Value of Circulating Tumor Cell and Peripheral Blood MRD Assessment in Multiple Myeloma

Does Chemokine Receptor Affect Sensitivity to Bortezomib Treatment in Myeloma?

Evaluating a Novel Combined Therapeutic Approach in Multiple Myeloma

Financial Toxicity: Searching for the Right Measurement Tool

Managing Bone Health, Pain, and Mobility in Patients With Myeloma: Palestinian Researchers Share Findings

Individualized, Risk-Prediction Model for Patients With Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma: Adding Elotuzumab to Standard Treatment

Black Women’s Health Study: Identifying Risk Factors for Multiple Myeloma

Novel Treatments for Multiple Myeloma May Emerge From Ephrin B2 Research

Relationship Between Age and Outcomes in Multiple Myeloma: A View From Latin America

Deep Dive Into Real-World Data on Daratumumab in Myeloma: Focus on Dosing Frequency

Machine Learning and M-Spike Values in Multiple Myeloma: Prognostic Potential

Maintenance Regimen After Autologous HCT in Relapsed Multiple Myeloma: Phase II Findings

Can a Precision-Based Exercise Program Improve Pain Control for Patients With Myeloma?

Case Report: Managing High-Risk Smoldering Multiple Myeloma With CAR T-Cell Therapy

Spinal Fracture After EBRT for Myeloma: Prediction and Prevention

Post-ASCT Maintenance Therapy for Multiple Myeloma: A Canadian Perspective

Comparing Triplet Regimens in Newly Diagnosed Myeloma: Is There a Clear Winner?

Screening for MGUS in High-Risk Groups May Reduce Health Disparities in Myeloma

More MagnetisMM-3 Results Support Elranatamab’s Potential in Myeloma

Targeting EZH2 to Counter Resistance to Anti-CD38 Immunotherapies in Myeloma

Induction Regimens in Myeloma: VRd Versus KRd

Can a Novel Scoring System Predict Outcomes With CAR T-Cell Therapy for Myeloma?

Second Primary Malignancies and Lenalidomide Treatment: Is There a Connection?

Standardized Assessment of Measurable Residual Disease Via FDG-PET/CT in Myeloma

Predicting Relapse After Transplantation in Myeloma: European Group Creates Novel Score

Updated Phase III IKEMA Results Support Isatuximab-Based Regimen for Relapsed Myeloma

Outcomes Improving for Young Adults Undergoing Autologous HCT for Myeloma

Update on New CAR T-Cell Therapy for Resistant Myeloma From Multicenter Study

Role of AI-Enabled Predictive Analytics for Patients With Multiple Myeloma

Research Offers Insights on Resistance Mechanisms of BCMA CAR T-Cell Therapy for Myeloma

Managing Cardiovascular Risk in Patients Being Treated for Myeloma

Dynamic Frailty in Myeloma: Indications for Prognosis and Management in Older Adults

Managing Myeloma and COVID-19 in the Post-Pandemic Era: Consensus From the European Myeloma Network

Can Bortezomib Treatment in Myeloma Be Made Better With Novel Nanoparticles?

Can CXCR4 Inhibitor and G-CSF Improve Mobilization of Hematopoietic Stem and Progenitor Cells?

Can Microvesicles, Derived From Myeloma Cells, Be Used to Monitor Tumor Load?

Novel Approach to Risk Stratification in Patients With Myeloma Harboring Translocations

Shedding Light on LAMP5, Potential Contributor to Progression of Myeloma

Therapeutic Strategy Under Study in Myeloma Focuses on Telomere Stability

Potential Myeloma Clinical Marker: Study of Calprotectin Generates Interest

Real-World Infection Picture With Bispecific Antibody Therapy for Multiple Myeloma

Multiple Myeloma, CML, and Prostate Cancer: A Rare Triple Combination in a Single Patient

Epigenetic Regulation of Oncogenic Overexpression of ITGB7 in Myeloma Cells

Biophysical Properties Underlying Immunoglobulin Light Chain Amyloidogenicity in Myeloma

BCMA/CD19-Targeting Immunotherapy for Newly Diagnosed Multiple Myeloma

Potentiating Cell Death in Multiple Myeloma Cells: Focus on Regulation of ALK2 Activity

High-Risk Secondary Events in Myeloma May Necessitate More Aggressive Treatment

Combination Immunochemotherapy for Resistant Myeloma: Focus on Extramedullary Disease

Demographic Characteristics of Patients With Myeloma From the CARTITUDE Trial

ATLAS Trial: Maintenance Triplet Regimen After Transplantation in Multiple Myeloma

COLUMBA Trial: Subcutaneous Versus Intravenous Daratumumab Therapy for Resistant Myeloma

Phase III CASTOR Trial: Daratumumab-Based Regimen for Resistant Multiple Myeloma

Plitidepsin-Based Combination Therapy Under Study in Resistant Multiple Myeloma

Is Telehealth Exercise as Effective as Standard Exercise Protocols for Patients With Multiple Myeloma?

Activity of Teclistamab in Resistant Myeloma Demonstrated in Early-Phase Study

Polypharmacy and Potentially Inappropriate Medications: Predictors of Frailty in Older Patients With Hematologic Malignancies?

Is the Antigen GPRC5D an Immunotherapeutic Target in Resistant Multiple Myeloma?

Chromatin Regulator Mutations: Novel Predictors of Adverse Outcomes in Multiple Myeloma?

Therapeutic Implications of Novel Genomic Mutations in Resistant Multiple Myeloma

Phase III IKEMA Trial: Isatuximab, Carfilzomib, and Dexamethasone in Resistant Myeloma

Transcription Factor FOXM1: A Key Driver and Potential Therapeutic Target in Myeloma

Does Targeting Autophagy Impact the Efficacy of Proteasome Inhibitor Treatment in Myeloma?

Providing Comprehensive Genetics in Myeloma: Focus on Linked-Read Whole-Genome Sequencing

Risk of Breakthrough COVID Infection After Vaccination in Patients With Hematologic Malignancies

HDGF: A Novel Factor in Multiple Myeloma Biology Identified

Optimal Cutoff Value of Circulating Tumor Cells in Myeloma: Biomarker of Adverse Outcomes?

Does Initiation of Oral Anticancer Agent Therapy for Myeloma Affect Adherence to Medications for Chronic Conditions?

Total Marrow Irradiation During Tandem ASCT for Multiple Myeloma

Impact of CD56 Expression on Prognosis and Treatment Response in Multiple Myeloma

Novel Gene Signature May Predict Response to Selinexor in Multiple Myeloma

Impact of Overexpression of CDC20 on Clinical Outcomes in Multiple Myeloma

ERK1/2 and CDK4/6 Inhibitor Combination Under Study in Resistant Myeloma

Can a Risk Score Predict Early Severe Infection in Patients With Multiple Myeloma?

Psychiatric Disorders, Self-Harm, and Patients With Cancer, Including Myeloma

From the Haematological Malignancy Research Network: Expanded Database May Yield Insights in Myeloma

Pros and Cons of BCMA-Targeting Treatment of Multiple Myeloma

Can Plasma Cell–Free RNA Profiling Differentiate Myeloma From Its Premalignant Condition?

Survival Outcomes After Biochemical and Clinical Progression of Relapsed Myeloma

Rare Case of Smoldering Multiple Myeloma Coexisting With Gastrointestinal Amyloidosis

Disrupting Homeostasis in Myeloma Cells: Focus of Research on Novel Therapeutic Approach

PIM2 Kinase: A New Therapeutic Target in Multiple Myeloma?

CD98 Heavy Chain Protein and Myeloma: Preclinical Study of Novel Monoclonal Antibody

Melphalan Flufenamide Versus Pomalidomide in Combination Therapy for Myeloma: OCEAN Trial

Comparison of Assessment Techniques in Myeloma: Longitudinal MRD Versus Biochemical

Phase II FORTE Trial Compares Combination Therapies Plus ASCT in Multiple Myeloma

Research Findings Focus on Characterizing the Epigenetic Landscape in Multiple Myeloma

Can Nutritional Supplements Offset Transplant-Related Toxicities in Multiple Myeloma?

Daratumumab Plus Carfilzomib and Dexamethasone in Resistant Myeloma: CANDOR Trial Update

Is There a Connection Between Regular Aspirin Use and Mortality in Multiple Myeloma?

Are Fully Vaccinated Patients With Myeloma Likely to Experience Breakthrough COVID-19 Infections?

Research Update on Bispecific CAR T-Cell Therapy for Resistant Multiple Myeloma

Is There an International Standard of Care for Triple-Class–Exposed Patients With Multiple Myeloma?

Preclinical Results on New PET Tracer in Multiple Myeloma

Palliative Chemoradiotherapy Regimen Under Study in Multiple Myeloma

Novel PET Assessment of Response to Daratumumab Quadruplet in Multiple Myeloma

Predisposing Factors to Catheter-Related Thrombosis in Patients With Myeloma Undergoing ASCT

Pulmonary Arterial Hypertension: An Adverse Effect of Carfilzomib Therapy for Myeloma?

Bridging Radiation Therapy Plus Immunotherapy for Resistant Multiple Myeloma

Venetoclax Plus Pomalidomide and Dexamethasone in Resistant Multiple Myeloma

Does t(11;14) Translocation Affect Outcomes in Multiple Myeloma?

Patterns of Infectious Complications in Patients With Myeloma After BCMA CAR T-Cell Therapy

Lenalidomide Maintenance Therapy for Multiple Myeloma: Is Longer Better?

Are Black Patients With Myeloma as Likely as White Patients to Receive Palliative Radiotherapy?

From the Nordic Myeloma Study Group: Update on Carfilzomib-Based Maintenance Therapy

Triplet Regimen Under Study in Frail Patients Newly Diagnosed With Multiple Myeloma

Early-Phase Study of KITE-585 in Resistant Multiple Myeloma

Antiemetic Option Under Study for Patients Receiving High-Dose Melphalan for Multiple Myeloma

Is Isatuximab Plus Carfilzomib/Dexamethasone the New Standard of Care in Relapsed Multiple Myeloma?

Autologous Peripheral Blood SCT for Myeloma: Trends in Cause-Specific Mortality

Cohort 2 of KEYNOTE-023: Pembrolizumab-Based Combination for Resistant Myeloma

Can Adding Clarithromycin to Lenalidomide/Dexamethasone Improve Outcomes in Myeloma?

Chemomobilization for Stem Cell Transplantation in Patients With Multiple Myeloma

Isatuximab Under Study in Daratumumab-Refractory Multiple Myeloma

Screening Technique for Early Identification and Treatment of Myeloma Under Study in Iceland

EMN09 Study: Is Carfilzomib, Bendamustine, and Dexamethasone Effective in Treating Advanced Myeloma?

Preclinical Immunomodulatory Strategy for Optimizing Immunotherapy in Myeloma

TOURMALINE-MM1: Overall Survival Outcomes With All-Oral Regimen

CARTITUDE-1 Trial: Targeting BCMA With CAR T-Cell Therapy for Myeloma

Interim Analysis of Phase III Trial of Combination Therapies for Resistant Myeloma

Does Early Combination Therapy Impact Renal Response and Survival in Multiple Myeloma?

COVID-19 and Myeloma: Antibody Responses Against SARS–CoV-2 in Elderly Patients

Low-Dose Venetoclax Under Study in Myeloma Harboring t(11;14) Translocation

Maintenance Therapy for Myeloma: Can Minocycline Reduce the Symptom Burden?

Cost of Disease Progression for Patients With Multiple Myeloma

Rare Case of Extramedullary Disease in Patient With Multiple Myeloma

Acquired Factor X Deficiency and Multiple Myeloma: Case Report

Dual Inhibitor of PI3K and HDAC Under Study in Multiple Myeloma

Case of Therapy-Related AML and Myeloma: Decitabine/Venetoclax and Daratumumab

Efficacy of High-Dose Carfilzomib in MRD-Negative Multiple Myeloma

Subcutaneous Adipose Tissue Radiodensity: Prognostic Indicator in Myeloma?

Rare Case of Multiple Myeloma and Echinococcus Granulosus Infection

Can Prognosis Be Linked to Esterase Gene Expression in Myeloma?

Case Study: Immunomodulatory Mechanism and Antimyeloma Effect of Daratumumab

IMWG Offers Updated Recommendations for Managing Myeloma-Related Bone Disease

Daratumumab-Based Regimens and Minimal Residual Disease in Patients With Myeloma

Mycobacterium Abscessus and SARS–CoV-2 Coinfection: Case Report in Myeloma

Renal Response and Outcomes in Myeloma: Carfilzomib- or Bortezomib-Based Therapy

Daratumumab-Based Therapy for Newly Diagnosed Myeloma: Patient-Reported Outcomes From MAIA Trial

Autologous SCT in Multiple Myeloma: To Cryopreserve or Not to Cryopreserve

COVID-19 and Multiple Myeloma: View From the UK Thames Valley Cancer Alliance

Addition of Beta-Blockers to Pomalidomide in Treatment of Multiple Myeloma

Panobinostat Dosing Regimens With SQ Bortezomib/Dexamethasone in Resistant Myeloma

Can Protein Expression Predict Response to Combination Therapy for Multiple Myeloma?

Case Report: Underlying Immunodeficiency and Early-Stage Multiple Myeloma

Update on Diagnostic Criteria and Imaging Techniques in Multiple Myeloma

Smoldering Multiple Myeloma: Defining the Threshold for Treatment

Is Immunotherapy Safe for Patients With Myeloma and HBV Infection?

Tracking Rare Bowel Perforations in Patients With Multiple Myeloma

Long-Term Treatment Strategy for Myeloma: Optimal Selections Based on Stage

Case Report: Multiple Myeloma Presenting as Seemingly Benign Scalp Mass

Triplet Therapy for Resistant Multiple Myeloma: Real-World View

Once-Weekly Selinexor Plus Bortezomib and Dexamethasone for Multiple Myeloma

Real-World Use of Measurable Residual Disease Testing in Multiple Myeloma

Comparing Immunomodulatory Agents in Myeloma at First Relapse: OPTIMISMM Trial

Study Analyzes Racial Differences in Treatment and Outcomes in Multiple Myeloma

‘Good-Risk’ Myeloma: Study Finds Genomic Markers Prognostic of Prolonged Survival

Maintenance Therapy With Ixazomib in Newly Diagnosed Multiple Myeloma

COVID-19 and Multiple Myeloma: Update From Stockholm

Triplet Regimen and Transplantation in Recently Diagnosed Multiple Myeloma

Optimizing Lenalidomide-Based Therapy for Myeloma: Focus on Plasma Concentration

Chinese Herbal Medicine: Potential Benefits for Patients With Multiple Myeloma?

Bovine Pestivirus: Novel Oncolytic Virotherapy Under Study in Myeloma

Are Education Levels Predictive of Outcomes in Multiple Myeloma?

COVID-19 and Myeloma: Characteristics of Infection and Serologic Response at Mount Sinai Hospital

Denosumab Versus Zoledronic Acid for Myeloma-Related Bone Disease

Myeloma and COVID-19: Consensus on Management From European Myeloma Network

Phase II Trial Focuses on Isatuximab for Resistant Myeloma

Racial Disparities in First-Line Treatment of Myeloma: Focus on Bortezomib and Lenalidomide

Identifying High-Risk Genomic Predictors in Patients With Smoldering Multiple Myeloma

Biomarker May Predict Ultra High–Risk Genetic Features of Myeloma

Vitamin D Deficiency and Racial Differences in Disease Biology in Multiple Myeloma

Update on Role of Subcutaneous Daratumumab in Multiple Myeloma

Multiple Myeloma and COVID-19: Recommendations From an Expert Panel

Pomalidomide-Based Therapy for Multiple Myeloma: Results From MM-014 Trial

Second-Line Therapy for Myeloma: Adding Low-Dose Decitabine to Bortezomib

Measles Virus Vaccine Under Study in Multiple Myeloma

Detecting Resistance to Treatment in Multiple Myeloma With Liquid Biopsy

BTK Inhibitor Combination Therapy for Resistant Multiple Myeloma

COVID-19 and Multiple Myeloma: Effects of IL-6 Blockade

Tandem Autologous/Allogeneic Transplant for Myeloma: Long-Term Follow-up of CALGB 100001

Rare Case of Dual Multiple Myeloma and AML: Combination Therapy Active for Both

Early Results With Ruxolitinib-Based Treatment for Resistant Myeloma

Gamma Gap Measurement: Tracking Treatment Response in Multiple Myeloma

CENTAURUS Trial: Daratumumab Monotherapy for Smoldering Multiple Myeloma

Subcutaneous Versus Intravenous Daratumumab in Resistant Multiple Myeloma

CAR T-Cell Strategy for Myeloma: Two Targets, Fewer Relapses

Smoldering Multiple Myeloma: Treat With Lenalidomide or Observe?

Bortezomib- Versus Lenalidomide-Based Treatments in Multiple Myeloma

Adding Clarithromycin to Combination Therapy in Transplant-Ineligible Patients With Myeloma

Daratumumab-Based Combination Therapy in Newly Diagnosed Myeloma: GRIFFIN Study Update

Disparities in Treatment Initiation Among Patients With Multiple Myeloma

Early Research Findings on CAR T-Cell Therapy in Resistant Multiple Myeloma

AMG 420 T-Cell Therapy Induces Responses in Resistant Multiple Myeloma

Carfilzomib-Based Induction Regimen in Newly Diagnosed Multiple Myeloma

Venetoclax-Based Combination in Resistant Multiple Myeloma

Targeting B-Cell Maturation Antigen in Resistant Multiple Myeloma

Responses to Novel Drug Combination Among Patients With Multiple Myeloma

Can Antibiotics Prevent Infection in Patients With Newly Diagnosed Myeloma?

Immune Response to Neoantigens Sparks Research in Myeloma

What Effects Do Induction Therapy for Myeloma Have on Circulating Monocytes?

Measurable Residual Disease: The Future of Assessing Treatment Efficacy in Myeloma?

BCMA-Targeted Immunoconjugate for Resistant Multiple Myeloma

Physical Exercise in Patients With Newly Diagnosed Multiple Myeloma

Shedding Light on Elotuzumab’s Mechanism of Action in Treating Myeloma

miRNAs: Prognostic Biomarkers in Multiple Myeloma?

Study Finds Racial Disparities in Treatment Patterns Among Patients With Multiple Myeloma

Can Lenalidomide Delay Disease Progression of Smoldering Multiple Myeloma?

Carfilzomib, Panobinostat, Dexamethasone: Novel Combination in Resistant Myeloma

How Does Facility and Provider Volume Impact Survival in Multiple Myeloma?

Comparing Health-Care Costs Across Lines of Therapy for Multiple Myeloma

Risk Assessment and Survival Prediction in Patients With Multiple Myeloma

Supportive Care for Older Adults With Myeloma: Underuse of Guideline Recommendations?

ASCT in Myeloma: Will It Be Transplanted by Other Treatments?

Serum Immune Marker and Progression From MGUS to Multiple Myeloma

Early-Phase Study of Iberdomide Plus Dexamethasone for Resistant Multiple Myeloma

Daratumumab and Lenalidomide/Dexamethasone in Multiple Myeloma MAIA Trial

Two Phase III Trials Evaluating Daratumumab-Based Therapies for Multiple Myeloma

More Precise Prognostic Index in Myeloma Relies Heavily on Cytogenetics

Carfilzomib-Based Therapy for Resistant Myeloma: Frailty Index and Outcomes

Pretreated Multiple Myeloma: Pomalidomide Plus Bortezomib/Dexamethasone

Pinpointing Best Dose of Immunotherapy (AMG 420) in Resistant Myeloma

Update on CART-BCMA Therapy for Resistant Multiple Myeloma

Selinexor Plus Low-Dose Dexamethasone for Refractory Multiple Myeloma

Combining PET-CT and Bone Marrow Assessment in Multiple Myeloma

CASSIOPEIA Trial: Daratumumab Combination Therapy for Newly Diagnosed Multiple Myeloma

Cardiovascular Adverse Events During Proteasome Inhibitor Therapy for Myeloma

Gait Speed and Grip Strength: Predictors of Outcome in Hematologic Malignancies?

Rare Case of Refractory Multiple Myeloma With Dura Mater Involvement

Phase I Study Findings With bb2121 in Resistant Myeloma

Is There a Role for Phytochemicals in the Treatment of Multiple Myeloma?

Current State of Carfilzomib Research for Resistant Multiple Myeloma

Purging Multiple Myeloma Cells Using Bortezomib and Lenalidomide

ABCG2 Polymorphisms in Multiple Myeloma

Potential of Targeting Adipocytes in Treatment of Myeloma

Salvage Autologous Stem Cell Transplantation for Multiple Myeloma: Patient-Reported Outcomes

Epigenetic Inhibitors in Multiple Myeloma Bone Disease: A New Frontier?

Multiple Myeloma and Cardiovascular Comorbidities

Combination Targeted Therapies Under Study in Myeloma

Prognostic Model for Transplant-Ineligible Patients With Multiple Myeloma

Newly Diagnosed Myeloma: Phase II Trial of Carfilzomib and Dexamethasone

Beyond Diagnostic Codes: A New Multiple Myeloma Algorithm

Novel Antibody-Drug Conjugate in Resistant Multiple Myeloma

Adding Cyclophosphamide to Lenalidomide/Dexamethasone in Resistant Myeloma

Bacteremia After Autologous Stem Cell Transplantation in Multiple Myeloma

Advancing Understanding of the Efficacy of Immunomodulatory Drugs in Myeloma

Gene Expression and Progression of Multiple Myeloma

ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide/Dexamethasone in Resistant Myeloma

Model for Collaborative Physician-Pharmacist Clinic in Multiple Myeloma

First-Line Treatment of Myeloma: Factors With Prognostic Value of Success

Lenalidomide Maintenance in Newly Diagnosed Patients: Myeloma XI Trial

Updated Results With Carfilzomib Triplet in Transplant-Eligible Patients With Myeloma

Cellular Therapy Targeting BCMA in Resistant Multiple Myeloma

Impact of Donor Clonal Hematopoiesis on Stem Cell Transplantation

Racial Disparities in Multiple Myeloma: Do Genomic Abnormalities Play a Role?

Frailty Index May Predict Survival in Newly Diagnosed Myeloma

Safety of Daratumumab in Relapsed or Refractory Multiple Myeloma

Novel Signaling Pathway: Route to Potential Therapy for Multiple Myeloma?

Access to Care: Thalidomide-Based Therapy in Multiple Myeloma

ELOQUENT-2 Trial: Long-Term Benefits of Triplet Therapy in Multiple Myeloma

Analysis of Bone Marrow Stromal Cells in Patients With Myeloma During Chemotherapy

Survival Benefits of Maintenance Therapies for Multiple Myeloma

Guidelines for Managing Clostridium Difficile Infection in Younger Transplant Recipients

End-of-Life Care After Allogeneic Hematopoietic Cell Transplantation

Investigating Link Between Cancer-Related Fatigue and Survival in Myeloma

Multiple Myeloma and Bone Metastases: Dosing Interval of Bone-Modifying Agents

Combination Therapy for Older Transplant-Ineligible Patients With Multiple Myeloma

Predictive Risk Factors for Outcome After Transplantation for Myeloma

Destabilizing NEK2 May Overcome Resistance to Treatment in Multiple Myeloma

Update on Reduced-Intensity Conditioning for Certain Hematologic Malignancies

Immunotherapy in Multiple Myeloma: Today and Tomorrow

Twice-Weekly Ixazomib May Benefit Some Patients With Newly Diagnosed Multiple Myeloma

Closer Look at Therapeutic Interventional Clinical Trials in Multiple Myeloma

Long-Term Outcomes Reported With Escalated Melphalan in Multiple Myeloma

Time to Myeloma Diagnosis: Room for Improvement

Is Stem Cell Transplant Still Relevant in Today’s Treatment of Multiple Myeloma?

Intensified Treatment Approach May Improve Survival in Some Patients With Myeloma

Carfilzomib in Resistant Myeloma: Once Weekly Versus Twice Weekly

Is Elotuzumab Monotherapy Beneficial in Patients With Smoldering Multiple Myeloma?

Novel Immunotherapy for Poor-Prognosis Relapsed Multiple Myeloma

PANORAMA-1 Trial in Multiple Myeloma: Patient-Reported Outcomes With Panobinostat

Noninterventional Study of Lenalidomide Plus Dexamethasone in Resistant Myeloma

New Research Finds Clues to Reducing Bortezomib-Linked Neuropathy

Addition of CAR T-Cell Therapy to Stem Cell Transplantation in Refractory Multiple Myeloma

How Closely Do Circulating Tumor Cells, Cell-Free DNA, and Bone Marrow Biopsies Agree?

Is Higher Body Mass Index a Risk Factor for Multiple Myeloma?

Potential of Folate-Targeted Therapies for Multiple Myeloma

Updated ASCO Guideline for Use of Bone-Modifying Agents in Multiple Myeloma

Is DCEP Chemotherapy a Viable Bridge to Definitive Therapy in Resistant Myeloma?

Screening Strategies in Individuals at Risk of Developing Multiple Myeloma

Are Recipients of Hematopoietic Cell Transplantation at Risk for Cognitive Decline?

Denosumab Versus Zoledronic Acid for Treating Myeloma With Bone Disease

Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma

ASPIRE Trial: Triplet Therapy in Relapsed or Refractory Multiple Myeloma

High-Dose Therapy Followed by Autologous Stem Cell Transplant for Multiple Myeloma

Considering Newer Agents in Managing Relapse in Resistant Myeloma

BCMA as a Therapeutic Target and Biomarker in Multiple Myeloma

Clinical Practice Update on Bone-Modifying Agents in Patients With Multiple Myeloma

Infection Prevention in Patients With Multiple Myeloma

Early Research Studies May Advance the Treatment of Multiple Myeloma

Carfilzomib and Cardiovascular Adverse Events in Patients With Multiple Myeloma

Novel Antibody Clone for Targeting Multiple Myeloma Cancer Cells

Survival and CRP Levels Prior to Transplantation in Patients With Multiple Myeloma

Novel Three-Part Treatment Sequence in High-Risk Multiple Myeloma

What Role, If Any, Does Obesity Play in MGUS and Multiple Myeloma?

Cost-Effectiveness Comparisons of Treatments for Heavily Pretreated Multiple Myeloma

Differences in Genetic Mutations in Blacks and Whites With Multiple Myeloma

Venetoclax Combination Therapy for Relapsed or Refractory Multiple Myeloma

Can Type of Myeloma Influence Response to Monoclonal Antibodies?

Multiple Myeloma Precancerous Disease and African Americans

Gene Signature in Predicting Response to Immunomodulatory Derivatives in Myeloma

Protein Kinases CK1-alpha and CK2 in Pathogenesis of Multiple Myeloma

Carfilzomib Versus Bortezomib in Relapsed or Refractory Multiple Myeloma

Prognostic Immune Biomarker in Newly Diagnosed Multiple Myeloma

Lenalidomide Maintenance After Transplantation in Multiple Myeloma

MRI Versus PET-CT in Symptomatic Patients With Multiple Myeloma

Bendamustine, Prednisone, and Bortezomib Treatment for Light Chain Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

Treatment Tolerability in Patients With Relapsed or Refractory Multiple Myeloma

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Induction and Maintenance Therapies With Bortezomib in Myeloma

Prognostic Impact of MRD-Negative Status in Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Subgroup Analyses Support Daratumumab Plus Lenalidomide Maintenance in Posttransplant Newly Diagnosed Multiple Myeloma